Prevalence of Cardiac Amyloidosis in Patients Undergoing Surgery for Lumbar Spinal Stenosis.
NCT ID: NCT05701397
Last Updated: 2023-01-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
200 participants
INTERVENTIONAL
2023-01-01
2024-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
If the ligament biopsy contains amyloid, patients will receive an echocardiogram, an ecg, biomarker testing, and a bone tracer scintigraphy diagnostic of cardiac amyloidosis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevalence of Cardiac Amyloidosis Among Patients With a History of Lumbar Spinal Stenosis.
NCT05701410
Cardiac Amyloidosis in Spinal Stenosis: the CASS-study
NCT04653675
Intracardiac Flow Assessment in Cardiac Amyloidosis
NCT05379101
Increasing Amyloidosis Awareness and Diagnosis Through Programmatic Imaging, Blood/Urine Testing and Pathology
NCT04983433
Validation of Different Diagnostic Modalities in the Detection of Cardiac Amyloidosis Among Patients With "Red Flags"
NCT06175858
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study group
Patients undergoing surgery for lumbar spinal stenosis. Patients will have a biopsy taken from the ligamentum flavum and test for the presence of amyloid. Patients with amyloid in the ligamentum flavum will be referred for a DPD scintigraphy.
DPD scintigraphy
Bone tracer scintigraphy, diagnostic for transthyretin cardiac amyloidsis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DPD scintigraphy
Bone tracer scintigraphy, diagnostic for transthyretin cardiac amyloidsis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \> 65 years
* Informed written consent
Exclusion Criteria
* Myelomatosis
* Monoclonal gammopathy of unknown significance, MGUS
* Morbus Waldenstrøm
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Steen Hvitfeldt Poulsen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Steen Hvitfeldt Poulsen
Professor, PhD, DMSci
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Cardiology, Aarhus University Hospital
Aarhus N, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1-10-72-116-22
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.